| Autor: |
Mengyun Lu, Li-Yuan Chen, Gairhe, Salina, Mazer, Adrien J., Anderson, Stasia A., Nelson, Jasmine N. H., Noguchi, Audrey, Siddique, Mohammad Abdul Hai, Dougherty, Edward J., Yvette Zou, Johnston, Kathryn A., Zu-Xi Yu, Honghui Wang, Shuibang Wang, Junfeng Sun, Solomon, Steven B., Vanderpoo, Rebecca R., Solomon, Michael A., Danner, Robert L., Elinoff, Jason M. |
| Předmět: |
|
| Zdroj: |
American Journal of Physiology: Lung Cellular & Molecular Physiology; Mar2022, Vol. 322 Issue 3, pL315-L332, 18p |
| Abstrakt: |
Treatment with mineralocorticoid receptor (MR) antagonists beginning at the outset of disease, or early thereafter, prevents pulmonary vascular remodeling in preclinical models of pulmonary arterial hypertension (PAH). However, the efficacy of MR blockade in established disease, a more clinically relevant condition, remains unknown. Therefore, we investigated the effectiveness of two MR antagonists, eplerenone (EPL) and spironolactone (SPL), after the development of severe right ventricular (RV) dysfunction in the rat SU5416-hypoxia (SuHx) PAH model. Cardiac magnetic resonance imaging (MRI) in SuHx rats at the end of week 5, before study treatment, confirmed features of established disease including reduced RV ejection fraction and RV hypertrophy, pronounced septal flattening with impaired left ventricular filling and reduced cardiac index. Five weeks of treatment with either EPL or SPL improved left ventricular filling and prevented the further decline in cardiac index compared with placebo. Interventricular septal displacement was reduced by EPL whereas SPL effects were similar, but not significant. Although MR antagonists did not significantly reduce pulmonary artery pressure or vessel remodeling in SuHx rats with established disease, animals with higher drug levels had lower pulmonary pressures. Consistent with effects on cardiac function, EPL treatment tended to suppress MR and proinflammatory gene induction in the RV. In conclusion, MR antagonist treatment led to modest, but consistent beneficial effects on interventricular dependence after the onset of significant RV dysfunction in the SuHx PAH model. These results suggest that measures of RV structure and/or function may be useful endpoints in clinical trials of MR antagonists in patients with PAH. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
